Your browser doesn't support javascript.
loading
Toolkit to Examine Lifelike Language (TELL): An app to capture speech and language markers of neurodegeneration.
García, Adolfo M; Johann, Fernando; Echegoyen, Raúl; Calcaterra, Cecilia; Riera, Pablo; Belloli, Laouen; Carrillo, Facundo.
Afiliação
  • García AM; Global Brain Health Institute, University of California, 505 Parnassus Ave, San Francisco, CA, 94143, USA. adolfo.garcia@gbhi.org.
  • Johann F; Cognitive Neuroscience Center, Universidad de San Andrés, Buenos Aires, Argentina. adolfo.garcia@gbhi.org.
  • Echegoyen R; Departamento de Lingüística y Literatura, Facultad de Humanidades, Universidad de Santiago de Chile, Santiago, Chile. adolfo.garcia@gbhi.org.
  • Calcaterra C; TELL Toolkit SA, Beethovenstraat, Netherlands. adolfo.garcia@gbhi.org.
  • Riera P; Cognitive Neuroscience Center, Universidad de San Andrés, Buenos Aires, Argentina.
  • Belloli L; TELL Toolkit SA, Beethovenstraat, Netherlands.
  • Carrillo F; Cognitive Neuroscience Center, Universidad de San Andrés, Buenos Aires, Argentina.
Behav Res Methods ; 2023 Sep 27.
Article em En | MEDLINE | ID: mdl-37759106
ABSTRACT
Automated speech and language analysis (ASLA) is a promising approach for capturing early markers of neurodegenerative diseases. However, its potential remains underexploited in research and translational settings, partly due to the lack of a unified tool for data collection, encryption, processing, download, and visualization. Here we introduce the Toolkit to Examine Lifelike Language (TELL) v.1.0.0, a web-based app designed to bridge such a gap. First, we outline general aspects of its development. Second, we list the steps to access and use the app. Third, we specify its data collection protocol, including a linguistic profile survey and 11 audio recording tasks. Fourth, we describe the outputs the app generates for researchers (downloadable files) and for clinicians (real-time metrics). Fifth, we survey published findings obtained through its tasks and metrics. Sixth, we refer to TELL's current limitations and prospects for expansion. Overall, with its current and planned features, TELL aims to facilitate ASLA for research and clinical aims in the neurodegeneration arena. A demo version can be accessed here  https//demo.sci.tellapp.org/ .
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Guideline Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Guideline Idioma: En Ano de publicação: 2023 Tipo de documento: Article